To promote patient safety and ensure the safest possible use of all biologics, including biosimilars, the Biologics Prescribers Collaborative is aligned on the following guiding principles:
- Considering the often debilitating or even life-threatening conditions experienced by people who regularly use biologics, all biosimilars-focused policy decisions should seek to, above all else, promote patient safety and preserve the patient-physician relationship.
- Distinguishable names for all biologic products, including biosimilars, are imperative to promote patient safety, strengthen patient-physician communication and enhance confidence in these vital medicines.
- Clear, active prescriber-pharmacist communication should occur in the event that an interchangeable biosimilar is substituted.
- Dispense as Written (DAW) authority should be used for specific clinical reasons for patient care; it should not have to be used as a fix for legislation that neglects to promote effective access to a patient’s medication history.